Plain-English translation of NCT06253611 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a new medication called , which works by modifying the bacteria in your gut, can help your immune system fight advanced stomach cancer when combined with two existing treatments: (an immunotherapy) and FOLFOX (chemotherapy). About 120 people will participate, with some receiving the new medication alongside the standard treatments and others receiving just the standard treatments.
Stomach cancer that has spread is difficult to treat, and researchers believe that the bacteria in your gut may play an important role in how well immunotherapy works. This trial is designed to see if improving your gut bacteria can make the standard cancer treatments more effective.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups: one group will take the new gut bacteria medication by mouth daily along with the standard intravenous immunotherapy and chemotherapy given every two weeks, while the other group receives only the standard treatments. You will have regular clinic visits, blood tests, and imaging scans (CT or MRI) to monitor how well the treatment is working, with a primary check at 4 months. You will also need to provide a tissue sample from your tumor for research purposes.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
France